Human antibodies against eotaxin and their use

Patent metadata

Field	Value
Publication number	US-10577413-B2
Application number	US-201615014945-A
Country	US
Kind code	B2
Filing date	Feb 3, 2016
Priority date	Mar 3, 2000
Publication date	Mar 3, 2020
Grant date	Mar 3, 2020

Abstract

Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-213/-213 VH and/or VL domains especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members and their use in methods of inhibiting or neutralising eotaxin, including methods of treatment or the human or animal body by therapy.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising a specific binding member that binds human eotaxin and a pharmaceutically acceptable excipient, carrier, buffer or stabilizer, wherein the specific binding member comprises:
(i) an antibody VH domain comprising a VH CDR1, a VH CDR2 and a VH CDR3, wherein said VH CDR1, VH CDR2 and VH CDR3 comprise the amino acid sequences of SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7, respectively; and
(ii) an antibody VL domain comprising a VL CDR1, a VL CDR2 and a VL CDR3, wherein said VL CDR1, VL CDR2 and VL CDR3 comprise the amino acid sequences of SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, respectively.

2. The pharmaceutical composition of claim 1 , wherein the specific binding member comprises the CAT-212 VH domain (SEQ ID NO:2).

3. The pharmaceutical composition of claim 1 , wherein the specific binding member comprises the CAT-212 VL domain (SEQ ID NO:4).

4. The pharmaceutical composition of claim 1 , wherein the specific binding member comprises the CAT-212 VH domain (SEQ ID NO:2) and the CAT-212 VL domain (SEQ ID NO:4).

5. The pharmaceutical composition of claim 1 , wherein the specific binding member comprises an scFv antibody molecule.

6. The pharmaceutical composition of claim 1 , wherein the specific binding member comprises an antibody constant region.

7. The pharmaceutical composition of claim 1 , wherein the specific binding member comprises a whole antibody.

8. The pharmaceutical composition of claim 6 , wherein the specific binding member comprises an IgG4 constant region.

9. The pharmaceutical composition of claim 7 , wherein the specific binding member comprises an IgG4 constant region.

10. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in tablet, capsule, powder or liquid form.

11. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in the form of a parenterally acceptable aqueous solution.

Assignees

• Medimmune Ltd

Inventors

• Vaughan Tristan John
• Wilton Alison Jane
• Smith Stephen
• Main Sarah Helen

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P17/06

  Antipsoriatics · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title